Details of the SBP
| General Information of Synthetic Binding Protein (SBP) (ID: SBP000143) | ||||||
|---|---|---|---|---|---|---|
| SBP Name |
BiTE Acapatamab
|
|||||
| Synonyms |
AMG-160; AMG160
|
|||||
| Molecular Weight | 105.8 kDa | |||||
| Design Method | Traditional methods (Site-directed mutagenesis and/or Directed evolution) | |||||
| Highest Status | Phase I | |||||
| Sequence Length | 986 | |||||
| SBP Sequence |
>BiTE Acapatamab
QVQLVESGGGLVKPGESLRLSCAASGFTFSDYYMYWVRQAPGKCLEWVAIISDGGYYTYY SDIIKGRFTISRDNAKNSLYLQMNSLKAEDTAVYYCARGFPLLRHGAMDYWGQGTLVTVS SGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCKASQNVDTNVAWYQQKPGQAP KSLIYSASYVYWDVPSRFSGSASGTDFTLTISSVQSEDFATYYCQQYDQQLITFGCGTKL EIKSGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARI RSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISY WAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTS GNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCV LWYSNRWVFGGGTKLTVLGGGGDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPE VTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKE YKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIA VEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQ KSLSLSPGKGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSDKTHTCPPCPAPELLGGPSVF LFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYR CVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKN QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGN VFSCSVMHEALHNHYTQKSLSLSPGK |
|||||
| 3D Structure | ||||||
| Computationally Modelled Structure | ||||||
| Click to Save PDB File | ||||||
| Protein Scaffold Information of This SBP | ||||||
|---|---|---|---|---|---|---|
| Scaffold ID | PS018 | [1] | ||||
| Scaffold Name | BiTE | |||||
| Scaffold Class | Antibody fragment | |||||
| Fold Type | Beta-Sheets + Loops | |||||
| Binding Target(s) of This SBP (BTS) |
|---|
| BTS Name | Details | Mechanism | Application | Affinity | Research Organization | Ref |
|---|---|---|---|---|---|---|
| T-cell surface glycoprotein CD3 | Inhibitor | Prostate cancer [ICD-11: 2C82.Z] | N.A. | Amgen | [1] | |
| Glutamate carboxypeptidase 2 | Inhibitor | Prostate cancer [ICD-11: 2C82.Z] | N.A. | Amgen | [1] | |
| Clinical Trial Information of This SBP | ||||||
|---|---|---|---|---|---|---|
| NCT03792841 | Click to show the Detail | |||||
| Indication | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | |||||
| Phase | Phase I | |||||
| Title | A Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Prostate Specific Membrane Antigen Half-life Extended Bispecific T-cell Engager?AMG 160?in Subjects With Metastatic Castration-resistant Prostate Cancer | |||||
| Status | Recruiting | |||||
| Sponsor | Amgen | |||||
| NCT04631601 | Click to show the Detail | |||||
| Indication | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | |||||
| Phase | Phase I | |||||
| Title | A Master Protocol Evaluating the Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC) | |||||
| Status | Recruiting | |||||
| Sponsor | Amgen | |||||
| NCT04822298 | Click to show the Detail | |||||
| Indication | Non-small Cell Lung Cancer | |||||
| Phase | Phase I | |||||
| Title | Study of AMG 160 in Subjects With Non-Small Cell Lung Cancer | |||||
| Status | Terminated | |||||
| Sponsor | Amgen | |||||